Fevzi Altuntaş

3.2k total citations
178 papers, 1.5k citations indexed

About

Fevzi Altuntaş is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Fevzi Altuntaş has authored 178 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Hematology, 55 papers in Oncology and 38 papers in Genetics. Recurrent topics in Fevzi Altuntaş's work include Hematopoietic Stem Cell Transplantation (47 papers), Lymphoma Diagnosis and Treatment (31 papers) and Acute Myeloid Leukemia Research (19 papers). Fevzi Altuntaş is often cited by papers focused on Hematopoietic Stem Cell Transplantation (47 papers), Lymphoma Diagnosis and Treatment (31 papers) and Acute Myeloid Leukemia Research (19 papers). Fevzi Altuntaş collaborates with scholars based in Türkiye, Cambodia and United States. Fevzi Altuntaş's co-authors include Bülent Eser, Mustafa Çetın, İ̇smail Sarı, Ali Ünal, Emre Tekgündüz, Serdal Korkmaz, Mehmet Sinan Dal, Orhan Yıldız, Tuğçe Nur Yiğenoğlu and Sinem Namdaroğlu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fevzi Altuntaş

160 papers receiving 1.5k citations

Peers

Countries citing papers authored by Fevzi Altuntaş

Since Specialization

Citations

This map shows the geographic impact of Fevzi Altuntaş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fevzi Altuntaş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fevzi Altuntaş more than expected).

Fields of papers citing papers by Fevzi Altuntaş

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fevzi Altuntaş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fevzi Altuntaş. The network helps show where Fevzi Altuntaş may publish in the future.

Co-authorship network of co-authors of Fevzi Altuntaş

This figure shows the co-authorship network connecting the top 25 collaborators of Fevzi Altuntaş. A scholar is included among the top collaborators of Fevzi Altuntaş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fevzi Altuntaş. Fevzi Altuntaş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study 2025 ·Haematologica ·Muhıt Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, (unknown), Ying Chen, Alejandra Nieto, Fatih Demırkan, Pau Montesinos, Fevzi Altuntaş	1
2	Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma 2025 ·Diagnostics ·(unknown), (unknown), (unknown), Turgay Ulaş, Mehmet Sinan Dal, Fevzi Altuntaş	0
3	Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias 2025 ·Bone Marrow Transplantation ·(unknown), Tayfur Toptaş, Mehmet Sinan Dal, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tuğçe Nur Yiğenoğlu, Mehmet Ali Erkurt, Turgay Ulaş, Fevzi Altuntaş	1
4	Solitary Plasmacytomas: Current Status in 2025 2025 ·Hematology Reports ·Umur Hatipoğlu, (unknown), Turgay Ulaş, Mehmet Sinan Dal, Fevzi Altuntaş	0
5	Efficacy of Ruxolitinib in the management of chronic GVHD 2024 ·Transfusion and Apheresis Science ·(unknown), Mehmet Ali Erkurt, (unknown), (unknown), İlhami Berber, (unknown), (unknown), Sinem Namdaroğlu, (unknown), (unknown), (unknown), (unknown), Serdal Korkmaz, Mehmet Sinan Dal, Turgay Ulaş, Fevzi Altuntaş	1
6	What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease? 2024 ·Transfusion and Apheresis Science ·Tuğçe Nur Yiğenoğlu, Mehmet Ali Erkurt, Simten Dağdaş, (unknown), İrfan Kuku, (unknown), (unknown), (unknown), Mehmet Sinan Dal, Emın Kaya, Serdal Korkmaz, Turgay Ulaş, Fevzi Altuntaş	0
7	Is Ruxolitinib an Effective and Safe Therapy for Chronic Myeloproliferative Diseases? 2024 ·Acta Oncologica Turcica ·(unknown), (unknown), (unknown), (unknown), Tuğçe Nur Yiğenoğlu, (unknown), Mehmet Sinan Dal, Fevzi Altuntaş	1
8	Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey 2023 ·Journal of Chemotherapy ·(unknown), Mehmet Sinan Dal, Tuğçe Nur Yiğenoğlu, (unknown), (unknown), Semih Başçı, (unknown), Serdal Korkmaz, (unknown), Murat Albayrak, Abdulkadir Baştürk, Düzgün Özatlı, Mehmet Hilmi Doğu, Tuba Hacıbekiroğlu, Merih Kızıl Çakar, Turgay Ulaş, (unknown), (unknown), Bülent Eser, Fevzi Altuntaş	2
9	Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients 2021 ·Journal of Chemotherapy ·(unknown), Mehmet Sinan Dal, (unknown), Olga Meltem Akay, Özgür Mehtap, (unknown), Fehmi Hindilerden, (unknown), Tuğçe Nur Yiğenoğlu, Semih Başçı, Merih Kızıl Çakar, (unknown), Serdal Korkmaz, Turgay Ulaş, Gülsüm Özet, Burhan Ferhanoğlu, Meliha Nalçacı, Fevzi Altuntaş	8
10	Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey 2021 ·Medicine ·(unknown), Mehmet Sinan Dal, (unknown), (unknown), (unknown), (unknown), (unknown), Semih Başçı, Tahir Darçın, (unknown), (unknown), (unknown), (unknown), Tuğçe Nur Yiğenoğlu, Fevzi Altuntaş	0
11	Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma 2021 ·Leukemia Research ·(unknown), Tuğçe Nur Yiğenoğlu, Semih Başçı, (unknown), (unknown), Tahir Darçın, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Fevzi Altuntaş	6
12	Second allogeneic stem cell transplantation in acute leukemia patients: single-centre experience 2020 ·SHILAP Revista de lepidopterología ·(unknown), Tuğçe Nur Yiğenoğlu, Semih Başçı, (unknown), (unknown), (unknown), Mehmet Sinan Dal, Merih Kızıl Çakar, Fevzi Altuntaş	0
13	Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience 2020 ·TURKISH JOURNAL OF MEDICAL SCIENCES ·(unknown), Semih Başçı, Mehmet Sinan Dal, Merih Kızıl Çakar, (unknown), Tuğçe Nur Yiğenoğlu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tahir Darçın, (unknown), (unknown), Fevzi Altuntaş	4
14	The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors 2020 ·Transfusion and Apheresis Science ·Tuğçe Nur Yiğenoğlu, Semih Başçı, (unknown), (unknown), (unknown), (unknown), Tahir Darçın, (unknown), (unknown), (unknown), (unknown), Merih Kızıl Çakar, Mehmet Sinan Dal, Tuba Hacıbekiroğlu, Fevzi Altuntaş	1
15	Inferior prognosis in poor mobilizing myeloma patients 2020 ·Transfusion and Apheresis Science ·Tuğçe Nur Yiğenoğlu, Semih Başçı, (unknown), (unknown), (unknown), (unknown), Tahir Darçın, (unknown), (unknown), (unknown), Merih Kızıl Çakar, Mehmet Sinan Dal, Tuba Hacıbekiroğlu, Fevzi Altuntaş	5
16	Epidemiology and mortality in bacterial bloodstream infections in patients with hematologic malignancies 2019 ·The Journal of Infection in Developing Countries ·(unknown), (unknown), (unknown), (unknown), (unknown), Fazılet Duygu, Mustafa Ertek, Fevzi Altuntaş	13
17	Coexistence of chronic lymphocytic leukemia and multiple myeloma, do the roots of these entities originate from the same place? 2017 ·Clinical Case Reports ·(unknown), (unknown), Mehmet Sinan Dal, (unknown), Ali Kaya, Emre Tekgündüz, Fevzi Altuntaş	2
18	Primary brain T-cell lymphoma concomitant with CNS tuberculosis in a kidney transplant patient. 2009 ·Murat Hayri Sipahioğlu, Fevzi Altuntaş, (unknown), (unknown), Leylagül Kaynar, Olgun Kontaş, Oktay Oymak, Cengiz Utaş	1
19	The Role of Plasma Exchange in HELLP Syndrome 2005 ·Clinical and Applied Thrombosis/Hemostasis ·Bülent Eser, Muhammet Güven, Ali Ünal, Ramazan Coşkun, Fevzi Altuntaş, Murat Sungur, İbrahim Serdar Serin, İ̇smail Sarı, Mustafa Çetın	61
20	Laparoscopic Versus Open Splenectomy in the Management of Benign and Malign Hematologic Diseases: A Ten-Year Single-Center Experience 2005 ·Journal of Laparoendoscopic & Advanced Surgical Techniques ·Can Küçük, Erdoğan Sözüer, Engin Ok, Fevzi Altuntaş, Zeki Yılmaz	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact